BioSpace News Archive

Drug Development

Principia Presents Consistent Positive Data of PRN1008 for Immune Thrombocytopenia in Ongoing Phase 1/2 Trial

Investigational oral BTK inhibitor demonstrates rapid onset and increased treatment responses over time as well as a favorable tolerability profile in 31 patients who have no other treatment options

December 7, 2019
·
6 min read
Biotech Bay

Ceribell Announces Launch Of Clarity, Providing 24/7 Automatic Bedside Monitoring To Enhance EEG Capability

The first and only FDA-cleared rapid response EEG system that provides continuous bedside EEG monitoring with instantaneous seizure detection and alert

December 7, 2019
·
3 min read
Business

Janssen Presents Initial Results for BCMA CAR-T Therapy JNJ-4528 Showing Early, Deep and High Responses in the Treatment of Relapsed or Refractory Multiple Myeloma

Results from Phase 1b/2 CARTITUDE-1 to premiere in oral presentation at ASH 2019 (Abstract #577)

December 7, 2019
·
11 min read
Drug Development

Extended Follow-up Phase 3 Data Underscore Sustained Efficacy and Safety of IMBRUVICA® (ibrutinib) in the Treatment of Chronic Lymphocytic Leukemia (CLL)

Follow-up data from Phase 3 E1912 study (abstract #33) evaluating IMBRUVICA in combination with rituximab versus standard chemoimmunotherapy (FCR) showed that previously untreated patients (aged 70 or younger) with CLL lived longer and with sustained benefit, with superior progression-free survival and overall survival - two critical measures in oncology treatment success

December 7, 2019
·
17 min read
Business

IMBRUVICA® (ibrutinib) Combination Therapy Data From Two Studies and Long-Term Integrated Analysis Presented at ASH 2019 Show Efficacy and Safety in First-Line Treatment of Chronic Lymphocytic Leukemia

Follow-up data from Phase 3 E1912 study (Abstract #33) evaluating the investigational use of IMBRUVICA® in combination with rituximab versus fludarabine, cyclophosphamide and rituximab showed statistically significant difference in progression-free survival (PFS) and overall survival (OS) were maintained in previously untreated patients (ages 70 or younger) with chronic lymphocytic leukemia (CLL)

December 7, 2019
·
17 min read
Drug Development

Cellular Biomedicine Group Presents First Clinical Data of IIT Phase 1 Trial of C-CAR088, a Novel BCMA CAR-T, at the 61st Annual Meeting of the American Society of Hematology

Five Patients were included in the analysis; all five patients showed clinical improvement in as early as two weeks

December 7, 2019
·
6 min read
Xenon Pharmaceuticals Provides Updates on Partnered Neurology Pipeline Programs at the 2019 American Epilepsy Society (AES) Annual Meeting

Overview of Clinical Stage XEN901 and Related Patient Survey to be Presented in the “Genetic Epilepsies – Updates in the Science and Diagnosis” Exhibit in Room 318-319 on Sunday, December 8th

December 7, 2019
·
7 min read
BioMidwest

More than Seven-Year Analysis of Early Treatment with IMBRUVICA® (ibrutinib) Monotherapy Showed Improved Progression-Free Survival in Patients with Mantle Cell Lymphoma (MCL) that Relapsed or Were Unresponsive to Prior Regimen

With extended follow-up of up to 7.5 years, treatment with IMBRUVICA early on in therapy demonstrated higher rates of progression-free survival and complete response

December 7, 2019
·
14 min read
Drug Development

Verastem Oncology Presents Phase 2 PRIMO Study Data Evaluating Duvelisib in Relapsed or Refractory Peripheral T-Cell Lymphoma at the American Society of Hematology 2019 Annual Meeting

Duvelisib Achieves Overall Response Rate of 62% in Patients with Relapsed or Refractory PTCL with Manageable Safety Profile in Initial Phase of PRIMO Trial

December 7, 2019
·
16 min read
Drug Development

Sangamo and Pfizer Announce Updated Phase 1/2 Results Showing Sustained Increased Factor VIII Activity Through 44 Weeks Following SB-525 Gene Therapy Treatment

The first two patients treated with the 3e13 vg/kg dose achieved stable Factor VIII (FVIII) levels demonstrating durability in the normal range through 44 and 37 weeks, respectively

December 7, 2019
·
12 min read